Rosatom produces a radioisotope to improve cancer treatment

Published at: 26/12/2024 03:55 PM

Scientists from the Institute of Reactor Materials, part of the Russian state corporation Rosatom, have mastered the technology of producing the medical radioactive isotope, terbio-161, which will make it possible to treat cancer more effectively, the press service of the company's scientific division reported.

“It is planned to be used in the production of a wide range of next-generation radiopharmaceuticals,” he said.

The company sent tests of the new product for testing to the Granov Scientific Center for Radiology and Surgical Technologies of the Russian Ministry of Health, in St. Petersburg.

The deputy director of scientific work at the Granov Center, Andrei Stanzhevsky, stated that “preclinical studies show that the dose administered by the isotope terbio-161 is, on average, 1.5 times higher than that of a similar drug”.

“This makes it possible to reduce the amount of radiopharmaceutical administered compared to lutetium-based preparations, which will reduce the radiation burden on the patient and the irradiation of intact organs and tissues,” he added.

The Russian nuclear sector produces the world's widest range of stable, radioactive isotopes for medical use. More than 2.5 million patients worldwide are diagnosed and treated annually thanks to these products.

MINCYT